U.S. markets open in 16 minutes
  • S&P Futures

    4,123.25
    +3.00 (+0.07%)
     
  • Dow Futures

    33,570.00
    -61.00 (-0.18%)
     
  • Nasdaq Futures

    13,889.00
    +80.25 (+0.58%)
     
  • Russell 2000 Futures

    2,228.60
    -2.00 (-0.09%)
     
  • Crude Oil

    60.45
    +0.75 (+1.26%)
     
  • Gold

    1,739.80
    +7.10 (+0.41%)
     
  • Silver

    25.28
    +0.41 (+1.66%)
     
  • EUR/USD

    1.1937
    +0.0020 (+0.17%)
     
  • 10-Yr Bond

    1.6640
    -0.0110 (-0.66%)
     
  • Vix

    17.02
    +0.33 (+1.98%)
     
  • GBP/USD

    1.3717
    -0.0025 (-0.18%)
     
  • USD/JPY

    109.2680
    -0.1080 (-0.10%)
     
  • BTC-USD

    62,914.90
    +2,474.65 (+4.09%)
     
  • CMC Crypto 200

    1,338.68
    +44.10 (+3.41%)
     
  • FTSE 100

    6,886.62
    -2.50 (-0.04%)
     
  • Nikkei 225

    29,751.61
    +212.88 (+0.72%)
     

Cerecor Shares Are Trading Higher On Positive CERC-002 Efficacy Data In COVID-19 Study

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Cerecor Inc (NASDAQ: CERC) shares gained premarket on the heels of final efficacy data, including 60-day mortality from the Phase 2 trial evaluating CERC-002 in hospitalized patients with COVID-19 associated pneumonia and acute respiratory distress syndrome (ARDS).

  • This analysis updates the preliminary topline data reported in January.

  • The updated data demonstrated a higher proportion of patients alive and free of respiratory failure over the 28-day study period (primary endpoint) compared to placebo.

  • At both the 28-day and the 60-day final timepoints, an approximately 50% trend in mortality reduction (22.5% vs. 10.8%) was observed.

  • Efficacy was highest in patients over the age of 60.

  • CERC-002 showed statistically significant efficacy on top of corticosteroids and standard of care treatments in COVID-19 ARDS.

  • The treatment was well-tolerated, with no drug-related serious adverse effects were reported.

  • The Company plans to meet with FDA to discuss the potential path to Emergency Use Authorization and approval.

  • Price Action: CERC shares were trading 13.9% higher at $4.25 in the premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.